Skip to main content

Table 2 Summary of adverse events

From: A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

  Prasugrel Placebo
  (n = 41) (n = 19)
Any hemorrhagic event, n (%)   
Required medical attention 0 0
Treatment-emergent 8 (19.5) 1 (5.3)
Possibly related to study drug 6 (14.6) 1 (5.3)
Any non-hemorrhagic event, n (%)   
Serious 8 (19.5) 4 (21.1)
Study drug discontinuation 2 (4.9) 0
Treatment-emergent 31 (75.6) 17 (89.5)
Possibly related to study drug 2 (4.9) 0
Any event, n (%)   
Serious 8 (19.5) 4 (21.1)
Study drug discontinuation 2 (4.9) 0
Treatment emergent 34 (82.9) 17 (89.5)
Possibly related to study drug 8 (19.5) 1 (5.3)